Systematic mutational analysis reveals an essential role of N275 in IgE stability
- 20 August 2024
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 121 (12) , 3782-3795
Abstract
Therapeutic antibodies have predominantly been IgG‐based. However, the ongoing clinical trial of MOv18 IgE has highlighted the potential of using IgE antibodies in cancer therapy. While extensive studies targeting IgG glycosylation resulted in a rational basis for the development of enhanced biotherapeutics, IgE glycosylation remains an area with limited analyses. Previous studies on the role of IgE glycosylation present conflicting data with one study emphasizing the importance of N275 and T277 residues for FcεRI binding whereas another asserts the nonsignificance of IgE glycosylation in receptor interaction. While existing literature underscores the significance of glycans at the N275 position for binding to FcεR1 receptor and initiation of anaphylaxis, the role of other IgE glycosylation sites in folding or receptor binding remains elusive. This study systematically investigates the functional significance of N‐linked glycosylation sites in the heavy chain of IgE which validates the pivotal role of N275 residue in IgE secretion and stability. Replacement of this asparagine to non‐amine group moieties does not affect IgE function in vitro, yet substitution with aspartic acid compromises antibody yield. The deglycosylated IgE variant exhibits superior efficacy, challenging the conventional importance of glycosylation for effector function. In summary, our study unveils an intricate relationship between N‐glycosylation sites and the structural–functional dynamics of IgE antibodies. Furthermore, it offers novel insights into the IgE scaffold, paving the way for the development of more effective and stable IgE‐based therapeutics.Keywords
This publication has 35 references indexed in Scilit:
- Analysis of Protein Glycosylation in the ER2017
- Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic diseaseJournal of Allergy and Clinical Immunology, 2017
- Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseasesJournal of Allergy and Clinical Immunology, 2016
- IgE Immunotherapy Against Cancer2015
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cellsCancer Immunology, Immunotherapy, 2007
- An overview of the association between allergy and cancerInternational Journal of Cancer, 2006
- Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cellsEuropean Journal of Immunology, 2003
- Comparison of IgE and IgG antibody-dependent cytotoxicityin vitro and in a SCID mouse xenograft model of ovarian carcinomaEuropean Journal of Immunology, 1999
- Effect of trimming inhibitors on the secretion and biological activity of a murine IgE monoclonal antibodyMolecular Immunology, 1987